Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Thomas McCoy Roberts, Ph.D.

Concepts

This page shows the publications Thomas Roberts has written about Receptor, erbB-2.
Connection Strength

0.222
  1. Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers. Oncogene. 2020 01; 39(1):50-63.
    View in: PubMed
    Score: 0.100
  2. PI3K-p110a mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. Oncogene. 2016 07 07; 35(27):3607-12.
    View in: PubMed
    Score: 0.076
  3. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med. 2016 07; 22(7):723-6.
    View in: PubMed
    Score: 0.020
  4. The p110a and p110ß isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev. 2012 Jul 15; 26(14):1573-86.
    View in: PubMed
    Score: 0.015
  5. Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor. Proc Natl Acad Sci U S A. 1992 Nov 01; 89(21):10435-9.
    View in: PubMed
    Score: 0.004
  6. Extracellular calcium mimics the actions of platelet-derived growth factor on mouse fibroblasts. Cell Growth Differ. 1992 Mar; 3(3):157-64.
    View in: PubMed
    Score: 0.004
  7. Modulation of a Mr 175,000 c-neu receptor isoform in G8/DHFR cells by serum starvation. J Biol Chem. 1990 Jun 25; 265(18):10746-51.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.